Jim Young1, Martin Potter2, Joseph Cox3, Curtis Cooper4, John Gill5, Mark Hull6, Sharon Walmsley7, Marina B Klein2. 1. Department of Medicine, Division of Infectious Diseases/Chronic Viral Illness Service, Royal Victoria Hospital, McGill University Health Centre, Montréal, Que. ; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. 2. Department of Medicine, Division of Infectious Diseases/Chronic Viral Illness Service, Royal Victoria Hospital, McGill University Health Centre, Montréal, Que. 3. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Que. ; Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University Health Centre, Montréal, Que. 4. The Ottawa Hospital - General Campus, Ottawa, Ont. 5. Southern Alberta HIV Clinic, Calgary, Alta. 6. BC Centre for Excellence in HIV/AIDS, Department of Medicine, University of British Columbia, Vancouver, BC. 7. University Health Network, University of Toronto, Toronto, Ont.
Abstract
BACKGROUND: Uptake of treatment for hepatitis C virus (HCV) is low in Canada despite its publicly funded health care system. We explored the uptake of HCV treatment within the Canadian Co-infection Cohort to determine if some treatment centres have been more successful than others at starting patients with HIV-HCV coinfection on HCV treatment. METHODS: We estimated the variation between 16 centres in the uptake of HCV treatment using a Weibull time-to-event model with adjustment for patient characteristics that are thought likely to influence the uptake of treatment. We asked the principal investigator at each centre about access to hepatitis-related specialists and services and the importance of various criteria when determining if a patient with HIV-HCV coinfection should receive treatment for HCV. RESULTS: Among 681 untreated patients in the Canadian Co-infection Cohort, 163 patients with HIV-HCV coinfection started HCV treatment over a period of 1827 patient-years (9 per 100 patient-years). Even after adjustment for case mix, there was still appreciable variation in treatment uptake between centres, with mean hazard ratios of 0.43 (95% credible interval 0.11-1.3) and 3.6 (95% credible interval 1.7-8.4) for the centres least and most likely to start an average patient with HIV-HCV coinfection on HCV treatment. The most important criteria reported by principal investigators for determining eligibility for treatment were severity of fibrosis, current psychiatric comorbidities, current alcohol intake, past HCV treatment and a history of reinfection with HCV. However, the opinions were wide-ranging: 8 of the 15 criteria elicited both the responses "less important" and "very important." INTERPRETATION: The magnitude of the centre effects and diverse opinions about the importance of treatment eligibility criteria suggest that provider-related barriers to HCV treatment uptake are as important as patient-related barriers.
BACKGROUND: Uptake of treatment for hepatitis C virus (HCV) is low in Canada despite its publicly funded health care system. We explored the uptake of HCV treatment within the Canadian Co-infection Cohort to determine if some treatment centres have been more successful than others at starting patients with HIV-HCV coinfection on HCV treatment. METHODS: We estimated the variation between 16 centres in the uptake of HCV treatment using a Weibull time-to-event model with adjustment for patient characteristics that are thought likely to influence the uptake of treatment. We asked the principal investigator at each centre about access to hepatitis-related specialists and services and the importance of various criteria when determining if a patient with HIV-HCV coinfection should receive treatment for HCV. RESULTS: Among 681 untreated patients in the Canadian Co-infection Cohort, 163 patients with HIV-HCV coinfection started HCV treatment over a period of 1827 patient-years (9 per 100 patient-years). Even after adjustment for case mix, there was still appreciable variation in treatment uptake between centres, with mean hazard ratios of 0.43 (95% credible interval 0.11-1.3) and 3.6 (95% credible interval 1.7-8.4) for the centres least and most likely to start an average patient with HIV-HCV coinfection on HCV treatment. The most important criteria reported by principal investigators for determining eligibility for treatment were severity of fibrosis, current psychiatric comorbidities, current alcohol intake, past HCV treatment and a history of reinfection with HCV. However, the opinions were wide-ranging: 8 of the 15 criteria elicited both the responses "less important" and "very important." INTERPRETATION: The magnitude of the centre effects and diverse opinions about the importance of treatment eligibility criteria suggest that provider-related barriers to HCV treatment uptake are as important as patient-related barriers.
Authors: Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway Journal: Eur J Gastroenterol Hepatol Date: 2010-03 Impact factor: 2.566
Authors: Juan Berenguer; Elena Rodríguez; Pilar Miralles; Miguel A Von Wichmann; José López-Aldeguer; Josep Mallolas; María J Galindo; Eva Van Den Eynde; María J Téllez; Carmen Quereda; Antoni Jou; José Sanz; Carlos Barros; Ignacio Santos; Federico Pulido; Josep M Guardiola; Enrique Ortega; Rafael Rubio; Juan J Jusdado; María L Montes; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García Journal: Clin Infect Dis Date: 2012-05-18 Impact factor: 9.079
Authors: Jason Grebely; Krista A Genoway; Jesse D Raffa; Gurbir Dhadwal; Tasleem Rajan; Grey Showler; Kate Kalousek; Fiona Duncan; Mark W Tyndall; Chris Fraser; Brian Conway; Benedikt Fischer Journal: Drug Alcohol Depend Date: 2007-11-09 Impact factor: 4.492
Authors: Nicole G Campos; Joshua A Salomon; Julie C Servoss; David P Nunes; Jeffrey H Samet; Kenneth A Freedberg; Sue J Goldie Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Karine Lacombe; Hélène Fontaine; Catherine Dhiver; Sophie Metivier; Eric Rosenthal; Teresa Antonini; Marc Antoine Valantin; Patrick Miailhes; Stanislas Harent; Dominique Batisse; Georges-Philippe Pageaux; Julie Chas; Hugues Aumaitre; Stephanie Dominguez; Thierry Allegre; Alain Lafeuillade; Eric Billaud; Pierre De Truchis; Philippe Perre; Vincent Leroy; Victor De Ledinghen; Philippe Sogni; François Dabis; Yue Zhao; Anne Filipovics; Larysa Fedchuk; Raoudha Akremi; Yacia Bennai; Dominique Salmon Ceron Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Sahar Saeed; Erin C Strumpf; Sharon L Walmsley; Kathleen Rollet-Kurhajec; Neora Pick; Valerie Martel-Laferrière; Mark Hull; M John Gill; Joseph Cox; Curtis Cooper; Marina B Klein; Jeff Cohen; Brian Conway; Curtis Cooper; Pierre Côté; Joseph Cox; John Gill; Shariq Haider; Marianne Harris; David Haase; Mark Hull; Julio Montaner; Erica Moodie; Neora Pick; Anita Rachlis; Danielle Rouleau; Roger Sandre; Joseph Mark Tyndall; Marie-Louise Vachon; Sharon Walmsley; David Wong Journal: Clin Infect Dis Date: 2016-01-06 Impact factor: 9.079
Authors: Sahar Saeed; Erin C Strumpf; Erica Em Moodie; Jim Young; Roy Nitulescu; Joseph Cox; Alexander Wong; Sharon Walmsely; Curtis Cooper; Marie-Lousie Vachon; Valerie Martel-Laferriere; Mark Hull; Brian Conway; Marina B Klein Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396